200 related articles for article (PubMed ID: 34284341)
1. Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.
Li L; Zhu M; Li DY; Guo HL; Hu YH; Xu ZY; Jing X; Chen F; Zhao F; Li YM; Xu J; Jiao Z
Int Immunopharmacol; 2021 Sep; 98():107827. PubMed ID: 34284341
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.
Huang L; Liu Y; Jiao Z; Wang J; Fang L; Mao J
Eur J Pharm Sci; 2020 Feb; 143():105199. PubMed ID: 31862313
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.
Hao GX; Huang X; Zhang DF; Zheng Y; Shi HY; Li Y; Jacqz-Aigrain E; Zhao W
Br J Clin Pharmacol; 2018 Aug; 84(8):1748-1756. PubMed ID: 29637588
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
5. Impact of Donor and Recipient
Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
[No Abstract] [Full Text] [Related]
6. Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus.
Wang CB; Zhang YJ; Zhao MM; Zhao L
Int Immunopharmacol; 2023 Nov; 124(Pt A):110866. PubMed ID: 37678026
[TBL] [Abstract][Full Text] [Related]
7. Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome.
Lu T; Zhu X; Xu S; Zhao M; Huang X; Wang Z; Zhao L
Pharm Res; 2019 Feb; 36(3):45. PubMed ID: 30719576
[TBL] [Abstract][Full Text] [Related]
8. Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.
Wang J; Huang L; Gao P; Hu Y; Ni Y; Zhu Z; Zhang L; Yang J; Zhang H; Fang L
Eur J Clin Pharmacol; 2021 Jan; 77(1):71-77. PubMed ID: 32803289
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study.
Liu J; Guo YP; Jiao Z; Zhao CB; Wu H; Li ZR; Cai XJ; Xi JY
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):453-466. PubMed ID: 32170643
[TBL] [Abstract][Full Text] [Related]
12. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.
Andrews LM; Hesselink DA; van Gelder T; Koch BCP; Cornelissen EAM; Brüggemann RJM; van Schaik RHN; de Wildt SN; Cransberg K; de Winter BCM
Clin Pharmacokinet; 2018 Apr; 57(4):475-489. PubMed ID: 28681225
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H
J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation.
Yang JW; Liao SS; Zhu LQ; Zhao Y; Zhang Y; Sun XY; Rao W; Qu W; Li WZ; Sun LY
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):75-83. PubMed ID: 25207550
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
[TBL] [Abstract][Full Text] [Related]
19. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule.
Chen X; Wang DD; Xu H; Li ZP
Xenobiotica; 2020 May; 50(5):606-613. PubMed ID: 31530218
[TBL] [Abstract][Full Text] [Related]
20. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
